The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?

Rudolf A. Werner, Alexander Weich, Malte Kircher, Lilja B. Solnes, Mehrbod S. Javadi, Takahiro Higuchi, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe, Constantin Lapa

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.

Original languageEnglish
Pages (from-to)6088-6100
Number of pages13
JournalTheranostics
Volume8
Issue number22
DOIs
Publication statusPublished - Jan 1 2018
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Peptide Receptors
Radioisotopes
Somatostatin Receptors
Therapeutics
Theranostic Nanomedicine
Sarcoidosis
Reading
Guidelines
Physicians

Keywords

  • Neuroendocrine tumor
  • Peptide receptor radionuclide therapy
  • PRRT
  • Somatostatin receptor
  • Theranostics

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Werner, R. A., Weich, A., Kircher, M., Solnes, L. B., Javadi, M. S., Higuchi, T., ... Lapa, C. (2018). The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go? Theranostics, 8(22), 6088-6100. https://doi.org/10.7150/thno.30357

The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go? / Werner, Rudolf A.; Weich, Alexander; Kircher, Malte; Solnes, Lilja B.; Javadi, Mehrbod S.; Higuchi, Takahiro; Buck, Andreas K.; Pomper, Martin G.; Rowe, Steven P.; Lapa, Constantin.

In: Theranostics, Vol. 8, No. 22, 01.01.2018, p. 6088-6100.

Research output: Contribution to journalReview article

Werner, RA, Weich, A, Kircher, M, Solnes, LB, Javadi, MS, Higuchi, T, Buck, AK, Pomper, MG, Rowe, SP & Lapa, C 2018, 'The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?', Theranostics, vol. 8, no. 22, pp. 6088-6100. https://doi.org/10.7150/thno.30357
Werner, Rudolf A. ; Weich, Alexander ; Kircher, Malte ; Solnes, Lilja B. ; Javadi, Mehrbod S. ; Higuchi, Takahiro ; Buck, Andreas K. ; Pomper, Martin G. ; Rowe, Steven P. ; Lapa, Constantin. / The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?. In: Theranostics. 2018 ; Vol. 8, No. 22. pp. 6088-6100.
@article{f4c4e8d43bb3459e8506b501b8ec04ea,
title = "The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?",
abstract = "More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.",
keywords = "Neuroendocrine tumor, Peptide receptor radionuclide therapy, PRRT, Somatostatin receptor, Theranostics",
author = "Werner, {Rudolf A.} and Alexander Weich and Malte Kircher and Solnes, {Lilja B.} and Javadi, {Mehrbod S.} and Takahiro Higuchi and Buck, {Andreas K.} and Pomper, {Martin G.} and Rowe, {Steven P.} and Constantin Lapa",
year = "2018",
month = "1",
day = "1",
doi = "10.7150/thno.30357",
language = "English",
volume = "8",
pages = "6088--6100",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "22",

}

TY - JOUR

T1 - The theranostic promise for Neuroendocrine Tumors in the late 2010s – Where do we stand, where do we go?

AU - Werner, Rudolf A.

AU - Weich, Alexander

AU - Kircher, Malte

AU - Solnes, Lilja B.

AU - Javadi, Mehrbod S.

AU - Higuchi, Takahiro

AU - Buck, Andreas K.

AU - Pomper, Martin G.

AU - Rowe, Steven P.

AU - Lapa, Constantin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.

AB - More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.

KW - Neuroendocrine tumor

KW - Peptide receptor radionuclide therapy

KW - PRRT

KW - Somatostatin receptor

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=85059303436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059303436&partnerID=8YFLogxK

U2 - 10.7150/thno.30357

DO - 10.7150/thno.30357

M3 - Review article

C2 - 30613284

AN - SCOPUS:85059303436

VL - 8

SP - 6088

EP - 6100

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 22

ER -